Glenmark Life Sciences Limited
NSE:GLS.NS
1,096.1 (INR) • At close November 8, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Glenmark Life Sciences Limited |
Symbool | GLS.NS |
Munteenheid | INR |
Prijs | 1,096.1 |
Beurswaarde | 134,308,421,300 |
Dividendpercentage | 2.74% |
52-weken bereik | 620.2 - 1,335.1 |
Industrie | Drug Manufacturers—Specialty & Generic |
Sector | Healthcare |
CEO | Dr. Yasir Yusufali Rawjee Ph.D. |
Website | https://www.glenmarklifesciences.com |
An error occurred while fetching data.
Over Glenmark Life Sciences Limited
Glenmark Life Sciences Limited develops, manufactures, and supplies non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers Olmesartan, Amiodarone, Telmisartan, Perindopril, Rosuvastatin, and Cilostazol for cardiovascular diseases; Oxcarbazepine, Zonisamide, Topiramate, Bupropion, Ropinirole, Riluzole, and Lacosamide for central nervous system diseases; Glimepiride, Teneligliptin, Vildagliptin, and Linagliptin
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (INR)
Cijfers zijn in miljoenen (INR)